Effect of Physostigmine and Verapamil on Active Avoidance in an Experimental Model of Alzheimer's Disease

References

• Bartus R. T., Dean R. L., Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417
   PubMed Web of Science ®Google Scholar
• Caltagirone C., Gainotti G., Masullo C. Oral administration of physostigmine does not improve cognitive or mnesic performance in Alzheimer's presenile dementia. International of Journal Neuroscience 1982; 16: 247–249
   PubMed Web of Science ®Google Scholar
• Cheng B., Mattson M. P. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bNGF. Experimental Neurology 1992; 117: 114–123
   PubMed Web of Science ®Google Scholar
• Coyle J. T., Price D. L., DeLong M. R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 19: 1184–1190
   Web of Science ®Google Scholar
• Davis K. L., Mohs R. C. Enhancement of memory with oral physostigmine in Alzheimer's disease. American Journal of Psychiatry 1982; 139: 1421–1424
   PubMed Web of Science ®Google Scholar
• Doble A. Excitatory amino acid receptors and neurodegeneration. Therapie 1995; 50: 319–337
   PubMed Web of Science ®Google Scholar
• Dokla C. P. J., Thal L. J. Effect of cholinesterase inhibitors on Morris water maze task behavior following lesions of nucleus basalis magnocellularis. Behavioral Neuroscience 1988; 102: 861–871
   PubMed Web of Science ®Google Scholar
• Farber J. L. The role of calcium in cell death. Life Science 1981; 29: 1289–1295
   PubMed Web of Science ®Google Scholar
• Gibson G. E., Peterson C. Calcium and the aging nervous system. Neurobiology of Aging 1987; 8: 329–343
   PubMed Web of Science ®Google Scholar
• Grobe-Einsler R. Clinical aspects of nimodipine. Clinical Neuropharmacology 1993; 16(suppl. 1)S39–S45
   Google Scholar
• Haroutunian V., Kanof P., Davis K. L. Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sciences 1985; 37: 945–952
   PubMed Web of Science ®Google Scholar
• Hepler D. J., Wenk G. L., Cribbs B. L., Olton D. S., Coyle T. Memory impairment following basal forebrain lesions. Brain Research 1985; 346: 8–14
   PubMed Web of Science ®Google Scholar
• Hoschle C. Do calcium antagonists have a place in the treatment of mood disorders?. Drugs 1991; 42: 721–729
   PubMed Web of Science ®Google Scholar
• Ingram D. K., Joseph J. A., Spangler E. L., Roberts D., Hengemihle J., Fanelli R. J. Chronic nimodipine treatment in aged rats: analysis of motor and cognitive effects and muscarinic-induced striatal dopamine release. Neurobiology of Aging 1994; 15: 55–61
   PubMed Web of Science ®Google Scholar
• Khachaturian Z. S. The role of calcium regulation in brain aging: reexamination of a hypothesis. Aging 1989; 1: 17–34
   PubMedGoogle Scholar
• Landfield P. W., Pitler T. A. Prolonged Ca2+-dependent afterhyperpolarizations in hippocampal neurons in aged rats. Science 1984; 226: 1089–1092
   PubMed Web of Science ®Google Scholar
• Landfield P. W. Calcium homeostasis in brain aging and Alzheimer's disease. Diagnosis and treatment of senile dementia, M. Bergener, B. Reisberg. Springer-Verlag, Berlin 1989; 276–287
   Google Scholar
• Lee E. H. Y., Lin W. R. Nifedipine and verapamil block the memory facilitating effect of corticotropin-releasing factorin rats. Life Sciences 1991; 48: 1333–1340
   PubMed Web of Science ®Google Scholar
• Leslie S. W., Chandler L. J., Barr E. M., Farrar R. P. Reduced calcium uptake by rat brain mitochondria and synaptosomes in response to aging. Brain Research 1983; 329: 177–183
   Web of Science ®Google Scholar
• LoConte G., Bartolini L., Casamenti F., Marconcini-Pepeu I., Pepeu G. Lesions of cholinergic forebrain nuclei: changes in avoidance behavior and scopolamine actions. Pharmacology. Biochemistry and Behavior 1982; 17: 933–937
   PubMed Web of Science ®Google Scholar
• Luiten P. G., Douma B. R., Van der Zee E. A., Nyakas C. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine. influence of aging and developmental drug treatment. Neurodegeneration 1995; 4: 307–314
   PubMedGoogle Scholar
• Mandel R. J., Thai L. J. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology 1988; 96: 421–425
   PubMed Web of Science ®Google Scholar
• Mandel R. J., Chen A. D., Connor D. J., Thai L. J. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. Journal of Pharmacology and Experimental Therapeutics 1989; 251: 612–619
   PubMed Web of Science ®Google Scholar
• Mattson M. P., Cheng B., Davis D., Bryant K., Liederburg I., Rydel R. E. p-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience 1992; 12: 376–389
   PubMed Web of Science ®Google Scholar
• Mattson M. P., Rydel R. E., Lieberburg I., Smith-Swintosky V. L. Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Annals of the New York Academy of Sciences 1993; 679: 1–21
   PubMed Web of Science ®Google Scholar
• Michaelis M. L., Johe K., Kitos T. E. Age-dependent alterations in synaptic membrane systems for Ca2+ regulation. Mechanisms of Aging and Development 1984; 25: 215–225
   PubMed Web of Science ®Google Scholar
• Miyamoto M., Shintani M., Nagaoka A., Nagawa Y. Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks. Brain Research 1985; 328: 97–104
   PubMed Web of Science ®Google Scholar
• Mohs R. C., Davis B. M., Johns C. A., Mathe A. A., Greenwald B. S., Horvath T. B., Davis K. I. Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry 1985; 142: 28–33
   PubMed Web of Science ®Google Scholar
• Murray C. L., Fibiger H. C. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 1985; 14: 1025–1032
   PubMed Web of Science ®Google Scholar
• Nakamura S., Tani Y., Maezono Y., Ishihara T., Ohno T. Learning deficits after unilateral AF64A lesions in the rat basal forebrain: role of cholinergic and noncholinergic systems. Pharmacology, Biochemistry and Behavior 1992; 42: 119–130
   PubMed Web of Science ®Google Scholar
• Narang P. K., Cutler N. R. Pharmacotherapy in Alzheimer's disease: Basis and rationale. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1986; 10: 519–531
   PubMed Web of Science ®Google Scholar
• Nelson S. R., Foltz F. M. Hypocalcemia and motor neuron degeneration in paraphysectionized frogs. Experimental Neurology 1983; 79: 763–772
   PubMed Web of Science ®Google Scholar
• Nyakas C., Buwalda B., Kramers R. J., Traber J., Luiten P. G. Postnatal development of hippocampal and neocortical cholinergic and serotonergic innervation in rat: effects of nitrite induced prenatal hypoxia and nimodipine treatment. Neuroscience 1994; 59: 541–559
   PubMed Web of Science ®Google Scholar
• Paxinos G., Watson C. The rat brain in stereotaxic coordinates. Academic Press, Sydney 1982; 1982
   Google Scholar
• Peterson C., Gibson G. E. Aging and 3, 4-diaminopyridine alter synaptosomal calcium uptake. Journal of Biological Chemistry 1983; 258: 11482–11486
   PubMed Web of Science ®Google Scholar
• Peterson C., Gibson G. E., Blass J. P. Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease. New England Journal of Medicine 1985; 312: 1063–1064
   PubMed Web of Science ®Google Scholar
• Peterson C., Goldman J. E. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 758–762
   Web of Science ®Google Scholar
• Peterson C., Ratan R. R., Shelanski M. L., Goldman J. E. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 7999–8001
   PubMed Web of Science ®Google Scholar
• Popović M., Jovanova-Nescarić K., Bokonjić D., Dobrić S., Popović N., Rosić N. Effect of verapamil on spontaneous motor activity and two-way avoidance learning in nucleus basalisslesioned rats. European Journal of Neuroscience 1995, suppl 8: 171
   Google Scholar
• Popović M., Jovanova-Nešć K., Popović N., Bokonjić D., Dobrić S., Rosić N., Rakić Lj. Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats. International Journal of Neuroscience 1996; 86: 281–299
   PubMed Web of Science ®Google Scholar
• Rosić N., Bignami G. Depression of two-way avoidance learning and enhancement of passive avoidance learning by small doses of physostigmine. Neuropharmacology 1970; 9: 311–316
   PubMed Web of Science ®Google Scholar
• Santucci A. C., Kanof P. D., Haroutunian V. Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology 1989; 99: 70–74
   PubMed Web of Science ®Google Scholar
• Sen A. P., Boksa P., Quirion R. Brain calcium channel related dihydropyridine and phenylalkylamine bindings sites in Alzheimer's, Parkinson's and Huntington's diseases. Brain Research 1993; 611: 216–221
   PubMed Web of Science ®Google Scholar
• Simonić A., Zupan G., Domino E. F. Effects of various cholinomimetic agents on passive avoidance behaviour in the nucleus basalis lesioned rats. Iugoslavica Physiologica et Pharmacologica Acta 1990; 26: 267–274
   Google Scholar
• Thal L. J., Fuld P. A., Masur D. M., Sharpless N. S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Annals of Neurology 1983; 13: 491–196
   PubMed Web of Science ®Google Scholar
• Thal L. J., Dokla C. P. J., Armstrong D. M. Nucleus basalis lesions: biochemical and immunocytochermcal recovery and effect of cholinesterase inhibitors on passive avoidance. Behavioral Neuroscience 1988; 102: 852–860
   PubMed Web of Science ®Google Scholar
• Yamazaki N., Kato K., Kurihara E., Nagaoka A. Cholinergic drugs reverse AF64A induced impairment of passive avoidance learning in rats. Psychopharmacology 1991; 103: 215–222
   PubMed Web of Science ®Google Scholar